ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.53 USD 9.63% Market Closed
Market Cap: 437.3m USD

ADC Therapeutics SA
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ADC Therapeutics SA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
EPS (Diluted)
-$1
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
EPS (Diluted)
CHf0
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
EPS (Diluted)
-$5
CAGR 3-Years
15%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
EPS (Diluted)
CHf5
CAGR 3-Years
303%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
EPS (Diluted)
CHf0
CAGR 3-Years
53%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
EPS (Diluted)
CHf0
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
397.6m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
HIDDEN
Show

See Also

What is ADC Therapeutics SA's EPS (Diluted)?
EPS (Diluted)
-1.5 USD

Based on the financial report for Sep 30, 2025, ADC Therapeutics SA's EPS (Diluted) amounts to -1.5 USD.

What is ADC Therapeutics SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
13%

Over the last year, the EPS (Diluted) growth was 58%. The average annual EPS (Diluted) growth rates for ADC Therapeutics SA have been 11% over the past three years , 13% over the past five years .

Back to Top